Publicaciones en las que colabora con Vicente Vicente García (23)

2022

  1. Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency

    Journal of Molecular Diagnostics, Vol. 24, Núm. 5, pp. 462-475

2021

  1. A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis

    American Journal of Hematology

2019

  1. Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing

    Annals of Medicine, Vol. 51, Núm. 2, pp. 141-148

2018

  1. Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis

    Platelets, Vol. 29, Núm. 2, pp. 192-195

  2. Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders

    Haematologica, Vol. 103, Núm. 1, pp. 148-162

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

  2. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

    Blood, Vol. 128, Núm. 9, pp. 1282-1289

  3. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

    Medicina Clinica

2011

  1. Diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna

    Medicina Clinica

  2. Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica

    Gaceta Sanitaria, Vol. 25, Núm. 4, pp. 274-281

  3. Fe de errores de "Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica"

    Gaceta Sanitaria

2008

  1. Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

    Laboratory Investigation, Vol. 88, Núm. 3, pp. 306-317

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

2006

  1. Erythrophagocytosis in de novo-philadelphia-positive acute leukemia of ambiguous lineage.

    Haematologica, Vol. 91, Núm. 8 Suppl

2004

  1. Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: Effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease

    Transfusion, Vol. 44, Núm. 5, pp. 771-776

1998

  1. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus

    Journal of Rheumatology, Vol. 25, Núm. 1, pp. 57-62

1997

  1. Trasplante autólogo con esquema BEAM en linfoma

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 46-49

1991

  1. Antibodies against hepatitis C virus in hemophiliacs: correlation with peripheral blood lymphocyte populations

    Medicina clínica, Vol. 96, Núm. 3, pp. 81-84

  2. Effect of hepatitis C virus infection on the lymphoid population in hemophiliacs [3]

    Blood

  3. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis

    American Journal of Hematology, Vol. 36, Núm. 4, pp. 249-254